Compare Biogen Inc (BIIB) vs Dell Technologies Inc (DELL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Dell Technologies Inc — how do they compare? Biogen Inc trades at $210.65 (market cap $30.86B), while Dell Technologies Inc trades at $495.8 (market cap $313.06B). The key difference: Dell Technologies Inc is far larger — about 10.1× Biogen Inc's market cap, and Dell Technologies Inc pays a 0.52% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | DELL | |
|---|---|---|
Market Cap | $30.86B | $313.06B |
Sector | Health | Technology |
52-Week High | $216.63 | $494.46 |
52-Week Low | $132.22 | $111.10 |
Enterprise Value | $37.93B | $332.64B |
Dividend Yield | — | 0.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $210.65, up 3.32% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a P/E of 37.1 and net income margin of 8.32%, supported by positive cash flow trends. Recent news highlights the acquisition of RayThera Inc. and raised 2026 guidance, reflecting strategic growth initiatives.
Outlook is positive with analyst consensus price target of $234.47, though risks include competitive pressures and earnings volatility. Investment opportunity lies in pipeline expansion and Alzheimer's drug traction, balanced by margin compression concerns from legacy MS portfolio declines.
Dell Technologies (DELL) is trading at $494.46, up 12.24% in the past 24 hours and near its all-time high of $514. The stock shows strong momentum with three consecutive earnings beats and bullish technical signals. Recent AI server demand from competitors like Lenovo and Super Micro has fueled sector-wide gains, with Dell benefiting from its positioning in the AI infrastructure market. The company's revenue grew to $95.57 billion in 2025, with net income reaching $4.59 billion.
Dell presents a compelling growth story driven by AI server demand and consistent earnings outperformance. However, the stock trades at premium valuations (P/E 38.61) and faces execution risks in a competitive hardware market. Analyst consensus remains bullish with a $503.76 price target, but investors should monitor debt levels and the sustainability of AI-driven revenue growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Dell Technologies Inc
VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses
Read more on DELL →
